Apollomics, Inc.
APLM
Rank in Stocks
#23611
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Share Price
$18.39
Last synced: 2026-11-11
Market Cap
$39.98M
Change (1 day)
-1.13%
Change (1 year)
-12.26%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Apollomics, Inc. (APLM)
Category
Healthcare
EPS for Apollomics, Inc. (APLM)
EPS as of December 2025 TTM: $-7.57
According to Apollomics, Inc.'s latest financial reports, its current EPS (TTM) is $-7.57. At the end of 2025 the company had an EPS of $-7.57, an increase over its 2024 EPS of $-52.80.
EPS history for Apollomics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-7.57 | 0.00% |
| 2025 | $-7.57 | -85.66% |
| 2024 | $-52.80 | -77.24% |
| 2023 | $-231.99 | 276.61% |
| 2022 | $-61.60 | 162.69% |
| 2021 | $-23.45 | 13.29% |
| 2020 | $-20.70 | 3,805.66% |
| 2019 | $-0.53 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -306.87% |
US
|
|
| $-7.07 | -6.61% |
US
|
|
| $-5.29 | -30.12% |
AU
|
|
| $12.88 | -270.15% |
BE
|
|
| $21.56 | -384.81% |
NL
|
Questions about Apollomics, Inc.'s earnings per share (EPS)
What is Apollomics, Inc.'s earnings per share (EPS)?
Apollomics, Inc.'s earnings per share (EPS) over the last twelve months is $-7.57, as of Dec 2025.
What was Apollomics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Apollomics, Inc.'s earnings per share (EPS) was $-7.57, compared with $-52.80 in 2024.
How has Apollomics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Apollomics, Inc.'s earnings per share (EPS) was highest in 2025 ($-7.57) and lowest in 2023 ($-231.99).
How does Apollomics, Inc.'s earnings per share (EPS) compare with similar companies?
Apollomics, Inc.'s earnings per share (EPS) ($-7.57) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.